Firms flex ADC muscles at ESMO

23 October 2023

The TROPION-Lung01 Phase III trial has yielded positive data for datopotamab deruxtecan (Dato-DXd), an investigational TROP2-directed antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TYO: 4568) and AstraZeneca (LSE: AZN).

These data were presented at the 2023 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.

"Datopotamab deruxtecan is central to the future we envision where ADCs improve upon and ultimately displace entrenched standards of care, like chemotherapy, in multiple cancer types"They showed a statistically-significant improvement for the primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK